Merck KGaA nears $3.5B SpringWorks deal Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Th Fri 25 April, 2025

Exploring Japan as a key market for your drug? Get the roadmap — join senior Japanese leaders to hear firsthand on the regulatory and pricing dynamics behind one of the world’s top pharma markets. Sign up now.

presented by AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

news Caribou lays off 32% of staff, cuts lupus cell therapy program before first patient AbbVie's immunology franchise remains a powerhouse, as Skyrizi, Rinvoq combine for $5B Merck KGaA closes in on SpringWorks deal at $3.5B price point Gilead's strong HIV business balances out low Covid and cancer drug sales Peer Review Paul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up leadership

VP, Clinical Development / CMO / CDO‬ Autonomy Bio Inc. San Francisco, CA 94107, USA COO / Head of Operations Autonomy Bio Inc. San Francisco, CA 94107, USA ‭ Regulatory Lead / Head of Regulatory‬ Autonomy Bio Inc. San Francisco, CA 94107, USA Senior Drug Development Clinician Weatherden London, UK Recruit talent with Endpoints Careers Contact Meg Estacio: mestacio@endpointsnews.com

Join us as we break down the latest oncology data, spotlight standout pipelines, and explore what’s coming next — reserve your spot today.

endpoints pharma Merck is ‘well-positioned’ on Keytruda ahead of threatened pharma tariffs, CEO says •  Merck’s Gardasil sales sink further amid China market pressure Halozyme sues Merck, alleging injectable Keytruda will infringe its patents Only two-thirds of FDA-approved biosimilars have launched, report finds Cassidy urges congressional reforms to 340B drug discount program after investigation Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

in case you missed it 1. Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact 2. Bristol Myers CEO signals dealmaking will be a top priority in 2025 •  Bristol Myers' transition moves forward as it raises 2025 revenue forecast 3. Roche takes steps to protect itself from tariffs, while Sanofi hangs back •  Roche CEO warns that tariffs could impact dealmaking